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Abstract
Background: Small promoters that recapitulate endogenous gene expression patterns are important for basic,
preclinical, and now clinical research. Recently, there has been a promising revival of gene therapy for diseases with
unmet therapeutic needs. To date, most gene therapies have used viral-based ubiquitous promoters–however,
promoters that restrict expression to target cells will minimize off-target side effects, broaden the palette of
deliverable therapeutics, and thereby improve safety and efficacy. Here, we take steps towards filling the need for
such promoters by developing a high-throughput pipeline that goes from genome-based bioinformatic design to
rapid testing in vivo.
Methods: For much of this work, therapeutically interesting Pleiades MiniPromoters (MiniPs; ~4 kb human DNA
regulatory elements), previously tested in knock-in mice, were “cut down” to ~2.5 kb and tested in recombinant
adeno-associated virus (rAAV), the virus of choice for gene therapy of the central nervous system. To evaluate our
methods, we generated 29 experimental rAAV2/9 viruses carrying 19 different MiniPs, which were injected
intravenously into neonatal mice to allow broad unbiased distribution, and characterized in neural tissues by X-gal
immunohistochemistry for icre, or immunofluorescent detection of GFP.
Results: The data showed that 16 of the 19 (84 %) MiniPs recapitulated the expression pattern of their design
source. This included expression of: Ple67 in brain raphe nuclei; Ple155 in Purkinje cells of the cerebellum, and
retinal bipolar ON cells; Ple261 in endothelial cells of brain blood vessels; and Ple264 in retinal Müller glia.
Conclusions: Overall, the methodology and MiniPs presented here represent important advances for basic and
preclinical research, and may enable a paradigm shift in gene therapy.
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Background
Interest in the identification of small promoters for recapitu-
lating unique gene expression patterns is longstanding, as
such promoters are widely used in basic and preclinical re-
search [1–6]. Recently, there has been a promising revival of
gene therapy for diseases with unmet treatment needs [7].
Most avant garde of these are Imlygic® and Glybera®, virus-
based gene therapies approved for marketing by the U.S.
Food and Drug Administration in 2015, and the European
Medicines Agency in 2013, respectively. To date, these and
most gene therapies have used viral-based ubiquitous pro-
moters. However, it has been recognized by leaders in the
field that “a more deliberate process of promoter selection
may be beneficial in the long run by determining the mini-
mum promoter activity that is necessary to tailor AAV-
mediated gene therapy to a particular neurological disease.”
[8]. It is anticipated that promoters that restrict expression
to target cells will minimize off-target side effects,
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broadening the palette of deliverable therapeutics, and
thereby improving safety and efficacy [8–10]. Recombi-
nant adeno-associated virus (rAAV) is the gene-therapy
vector of choice for many clinical applications, especially
in non- or slowly-dividing cells, which are typical of the
CNS [11–17]. However, the limited AAV-packaging
capacity of ~4.9 kb [18] leaves very little space for a pro-
moter. In contrast, mammalian promoters are generally
large and complex, with cis-regulatory modules (CRMs)
dispersed throughout the gene. Furthermore, identifying
CRMs and predicting their function remains a major
challenge [2, 19–21]. In this work, we take steps towards
filling the research and expanding clinical need for small
promoters with restricted expression by developing them
for use in rAAV for the brain and eye.
We accomplished this goal by building upon our previ-
ously developed “MiniPromoters” (MiniPs), human DNA
elements designed to drive expression in restricted cell types
[22–25]. Previously, we bioinformatically parsed the entire
human genome to identify genes suitable for MiniP design
[24]. Further selection steps included genes with therapeut-
ically interesting conserved expression patterns in human
and mouse adult brain [26], and conserved computationally-
predicted candidate regulatory regions (RRs). In general,
MiniP designs were ~4 kb, consisting of a PROM (~1.1 kb
at the transcription start site; range 254–3,536 bp) and mul-
tiple CRMs (~900 bp each; range 28–2,951 bp), which were
usually non-contiguous and typically repositioned 5′ of the
PROM. We named our MiniPs sequential by “Ple” number
(for Pleiades Promoter Project). Initially, MiniPs were tested
driving a reporter after being knocked-in, single-copy, site-
specific 5′ of the mouse Hprt gene. Key features of this stra-
tegy included: 1) a large-scale pipeline, to reduce the impact
of the expected high failure rate in promoter design; 2)
physiologically relevant expression, potentially more suitable
for therapeutic delivery; 3) human DNA, presumably de-
creasing our success when initially tested in mice, but favor-
ing translation to humans if positive; and 4) the expectation
that endogenous-like expression in mice best predicts a
similar expression will occur in humans. In total, 45 such
positive MiniPs have been developed [22, 24] and made
available to the research community (www.addgene.org and
www.jax.org).
However, we anticipate that not all MiniPs, which func-
tioned as single-copy site-specific knock-ins (KIs) in the
mouse genome, will also function specifically in rAAV. For
example: 1) multiple virus copies may increase and thereby
broaden expression; 2) developmentally-established epi-
genetic marks may not be acquired by a promoter intro-
duced after birth; and 3) most of the original Pleiades
promoters will need to be “cut down” to be useful in rAAV,
which may inadvertently remove essential elements. How-
ever, we have previously tested three MiniPs developed in
mice (one unaltered and two cut downs) in rAAV2 and
were encouraged by their success [22]. On the other hand,
this data set was small; thus, to draw a stronger conclusion
and to provide more resources for the field, in this study
we have evaluated a much larger set of 19 MiniPs. For this
evaluation, we established a two-step, relatively large-scale
high-throughput screening system for human MiniPs pack-
aged in rAAV and tested in mouse. After promoter design,
DNA was synthesized, cloned into our “plug and play”
rAAV2 genome plasmid, packaged as rAAV2/9 for broad
tropism, and injected intravenously into neonatal mice, with
histological analysis of expression in adult brain and eye [27].
The first step of the screening uses a highly-sensitive
historical-indirect reporter system, in which the MiniP drives
icre (improved cre recombinase [28]) in a cre-reporter
mouse. In the second screening step, representative success-
ful promoters were recloned driving the direct reporter em-
erald green fluorescent protein (EmGFP) [29] and the assay
performed again. By undertaking these studies with the smal-
lest and thus most challenging virus, rAAV, we anticipate
that successful promoters will have a wide use in other gene
therapy modalities such as lentivirus, adenovirus, retrovirus,
herpes simplex virus, plasmids, and nanoparticles.
Results and Discussion
Updated MiniPromoter virus pipeline allows for rapid
construct screening
We had previously scored every gene in the human genome
for suitability for MiniP design by assessing regulatory reso-
lution, a metric that favors small genes with clearly defined
conserved regions [24]. MiniPs were initially designed based
on information in primary literature, transcription start sites,
sequence boundaries, phylogenetic footprinting, and tran-
scription factor binding site predictions [24]. Now, as add-
itional genome-wide datasets such as RNAseq, and new
data and tools within projects such as FANTOM [30] and
JASPAR [31] become publically available, they were
exploited for bioinformatically-driven MiniP design and re-
design. In addition, compared to our previous work, the
current pipeline was intended to move directly from MiniP
design to a virus-based assay, decreasing the costs associated
with KI mouse engineering, greatly reducing turn-around
time, and making sequential redesigns feasible in the future.
In establishing this pipeline, we wanted a system that
transduced as many cells as possible and showed expres-
sion with a ubiquitous promoter in all relevant cell
types, such that any observed restriction would be at-
tributable to the promoter. Thus, we tested 15 control
rAAVs including: self-complementary and single-stranded
genomes; AAV9 and AAVrh.10 serotypes; CMV, smCBA,
CBA, CAGGS, and promoterless constructs; hGFP, GFP,
cre, icre, and EmGFP reporters; and the 3′-UTR wood-
chuck hepatitis virus post-transcriptional regulatory elem-
ent (WPRE). We used WPRE mut6, a DNA element
known to substantially increase expression levels but
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without promoter activity [32, 33]. Figure 1a depicts the
“plug and play” rAAV2 genome plasmid we developed,
with AAV2-based inverted terminal repeats (ITRs), an in-
tron, either icre or EmGFP reporters, with or without
WPRE. Restriction enzyme sites allowed for the rapid ex-
change of promoters, reporters, or removal of the intron
and/or WPRE. Figure 1b depicts the first evaluation step of
the pipeline, in which a MiniP drove icre, which perman-
ently removed the “stop” from a mouse genomic locus
where the ubiquitous ROSA26 promoter drove a “lox-stop-
lox-lacZ” allele, resulting in high-level expression of lacZ
wherever and whenever icre was expressed. Thus, this step
used an historical-indirect reporter of cre activity. Figure 1c
depicts the second evaluation step of the pipeline, in which
a positive MiniP was retested driving EmGFP, a direct re-
porter of MiniP expression, detected via epifluorescence or
immunofluorescence staining.
MiniPromoter selection surveyed a variety of design types
Figure 2 lists the 29 experimental viruses generated for
this project. The 19 MiniPs carried by these viruses were
all chosen for potential therapeutic utility. The majority of
our work consisted of P0 virus injections for both icre and
EmGFP viruses. A subset of EmGFP constructs were also
injected at P4, since it has been shown that the develop-
mental age at which virus is delivered to the mouse eye
determines the cell types most efficiently transduced [34].
Five previously designed MiniPs were tested “unaltered”
in rAAV2/9: Ple34 (CLDN5 RRs), Ple67 (FEV RRs), Ple94
(GPR88 RRs), Ple155 (PCP2 RRs), and Ple198 (SLC6A4
RRs) [22, 24]. KI mouse data for three of these MiniPs
(Ple34, Ple67, and Ple155) had been previously published
[22, 24], of which Ple67 was also known to drive expres-
sion in the eye following intravitreal rAAV delivery [22].
The remaining two MiniPs in this group (Ple94 and
Ple198), were chosen despite negative KI mouse data due
to their potential clinical impact, as we suspected de-
tection was a limitation with a subset of our previously
negative single-copy EGFP reporter KI mice [24]. Our
hypothesis was that the multi-copy rAAV system would
enhance low-level expression, allowing us to recapture
previously “negative” MiniPs.
A further eight previously designed MiniPs, which were
positive in KI mice, were chosen for “cut down” to ~2.5 kb
or smaller, after bioinformatics reanalysis identified regions
that were less likely to contribute to regulatory function
(Ple251 (C8ORF46 RRs), Ple253 (PITX3 RRs), Ple261
(CLDN5 RRs), Ple264 (NR2E1 RRs), Ple266 (S100B RRs),
Ple267 (UGT8 RRs), Ple302 (DCX RRs), and Ple304 (OLIG1
RRs)). The majority of the original Pleiades MiniPs require
such modification in order to be useful in the space-limited
rAAV as they were initially ~4 kb for KI mouse studies.
For two MiniPs (Ple301 (TNNT1 RRs) and Ple305
(OLIG1 RRs)) we undertook bioinformatically-driven
“base-pair modifications” that were divergent from the
reference human sequence, in favor of a transcription
factor consensus sequence designed to strengthen the
previously successful promoter. Thus, we included in
the study Ple301, which carried two base-pair modifica-
tions compared to our previous Ple232, which was posi-
tive in KI mice [22]. The base-pair modifications were
introduced to improve the core promoter region con-
taining downstream core elements (DCEs), which are
recognized by TFIID [35]. Similarly, Ple305 was a three
Fig. 1 “Plug and Play” rAAV2 genome plasmid used to clone MiniPromoters (MiniPs) upstream of icre or EmGFP enables high throughput
pipeline testing. a Plasmids were generated containing either the icre or the EmGFP reporter. An AsiSI site flanks a removable WPRE. MiniPs were
cloned at the MCS using a combination of the four available cut sites. The plasmids are subsequently used to generate single stranded rAAV.
b Screening step one, an historical-indirect reporter system. MiniPs drive expression of icre, which in turn recombines the endogenous loxP sites
and removes the stop sequence 5ʹ of the lacZ gene, thus driving expression of β-galactosidase from the strong ubiquitous ROSA26 promoter.
c Screening step two, a direct reporter system. MiniPs drive direct expression of EmGFP, which can be imaged by epifluorescence or signal
amplified using antibodies. bp, base pairs; ITR, inverted terminal repeat; MCS, multiple cloning site; WPRE, woodchuck hepatitis virus post-
transcriptional regulatory element
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base-pair modification of Ple304 (a cut-down described
above). The changes were designed to increase expres-
sion by strengthening the TATA-box and upstream B
recognition elements (BREs) [36, 37].
Three promoters were also chosen from the “literature”.
Two were representative of the extensive community re-
source developed by the VISTA enhancer project, the
main goal of which is to identify distant-acting non-
coding regulatory elements that drive developmental gene
expression in a region-specific manner [38]. VISTA en-
hancers are chosen using extreme evolutionary sequence
conservation and/or ChIP-seq data, and then tested com-
bined with a mouse minimal promoter (Hsp68) by ran-
dom insertion in the mouse genome, with expression
evaluated in E11.5 embryos. In our system, we tested two
of their small human enhancers that had highly-specific
brain expression: hs671 (forebrain; DPYD-AS1 intragenic
genomic location), and hs1218 (midbrain; OTX2-AS1 –
EXOC5 intergenic genomic location). A third literature
example was chosen due to its important therapeutic ap-
plication in Parkinson disease. Although, in our previous
work we were able to obtain regionalized expression with
a DBH-based MiniP in KI mice, there was no clear overlap
with tyrosine hydroxylase staining [24]. Thus, we choose
to test PRS2/3:Con; a DBH-based promoter that had been
successfully used in adenovirus in the rat adult brain [39].
Lastly, we computationally designed one completely
new MiniP for direct testing in rAAV to assess our de
novo design abilities. For this work, we chose NOV
(nephroblastoma overexpressed gene). Previously, be-
cause NOV had a poor RR score of 0.0439 primarily due
to a large genomic region [24], despite clear TSS/pro-
moter and RR elements, we had tested a retrofitted NOV
BAC in a Hprt KI mouse with promising positive results
[2]. Although a BAC construct may not delineate spe-
cific regulatory elements, it does provide genomic
boundaries for the regulatory region. Thus, we designed
a MiniP using elements within the NOV BAC, for testing
in virus.
Ubiquitous promoters demonstrate widespread
transduction
After an initial wide survey of methodologies, we fo-
cused on neo-natal intravenous delivery of single-
stranded rAAV in AAV9, due to its excellent capability
to transduce a variety of CNS cell types in our hands
and as described in the literature [27, 40, 41]. To evalu-
ate the reproducibility of these methods the expression
of icre from the CAGGS and EmGFP from the CAGGS
and smCBA ubiquitous promoters was analyzed. Con-
sistent staining was seen, with positive staining in all
brain regions, but reduced in areas such as the striatum,
Fig. 2 Twenty-nine rAAVs, carrying 19 MiniPromoters (MiniPs), from 17 gene/loci, resulted in 16 MiniPs with expression patterns related to the
gene/source. MiniPs in black text drive icre; MiniPs in green text drive a green fluorescent protein; horizontal lines group MiniP constructs; note
that the CLDN5-based MiniPs are separated in the table and thus highlighted in pink; BAC, bacterial artificial chromosome; bp, base pairs; EmGFP;
emerald green fluorescent protein; icre, improved cre recombinase; KI, knock-in; miniSOG, mini Singlet Oxygen Generator; NA, not applicable;
ORF, open reading frame; PMID, PubMed ID number; rAAV; recombinant adeno associated virus; ST, stereotaxic; VISTA RI, random insertion from
VISTA enhancer project; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element
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midbrain, ventral hindbrain, and Purkinje cells of the
cerebellum (Additional file 1: Figure S1). With the direct
EmGFP reporter, expression was markedly increased in
intensity and in number of positive cells when combined
with the WPRE.
These results are consistent with the literature on ubi-
quitous promoters, which indicates variation in their
cell-type specific expression. The cell-type variation in
ubiquitous promoter expression may result in inad-
equate reporting on the full spectrum of viral tropism
for a particular AAV and delivery method [42–44]. For
instance, the observation of poor expression in motor
neurons with the CBA ubiquitous promoter, only to find
strong expression when using a MeCP2-based promoter,
which has neuronal expression in the CNS [43]. Thus,
we propose that the true breadth of viral tropism in our
system will be determined by the overlap of ubiquitous
and specific promoters.
16 novel MiniPromoters with consistent restricted
expression
In total, 19 Pleiades MiniPs were tested in rAAV2/9.
Eighteen were tested driving icre in mice carrying a
“lox-stop-lox-lacZ” allele, an historical-indirect reporter.
Four of these were further tested driving either EGFP or
EmGFP direct expression reporters. To avoid duplica-
tion, we only present the GFP data for these four. Fi-
nally, one Pleaides MiniP was tested driving miniSOG, a
direct expression reporter. In all, we saw 16 MiniPs with
restricted expression: 11 in the brain, 10 in the eye, and
one in muscle.
The consistency of MiniPromoter constructs was
assessed by analyzing expression patterns in multiple an-
imals (Additional file 1: Figure S2). In the brain, all 19
MiniPromoter constructs showed ≥75 % consistency
with the figures presented (n ≥ 4 animals per construct).
In the eye, 11/13 MiniPromoter constructs showed ≥70
% consistency with the figures presented (n ≥ 4 animals
per construct).
MiniPromoters for the brain include restricted expression
in Raphe nuclei and blood brain barrier
Figure 3 presents the data for eight positive Pleiades
MiniPs driving icre. We chose to first test MiniPs with
the historical-indirect reporter system because of its high
sensitivity, since any expression of icre, from the neo-
natal introduction of the virus to the adult harvest,
would be captured by the strong genomic Gt(ROSA)26-
Sor promoter. Nevertheless, we were surprised by the
generalized pattern of positive staining that was sparse,
but widespread, and similar across all well-injected mice.
This “background” may have been due to non-specific
icre expression as a result of initial high viral copy num-
ber, the time required for appropriate epigenetic marks,
and transcription factor binding. However, superimposed
on this was the expected restricted expression for many
of the MiniPs, suggesting this problem resolves. For ex-
ample, two previously negative KI designs, Ple94 (GPR88
RRs) and Ple198 (SLC6A4 RRs), were positive and
expressed in the striatum and thalamus respectively – as
expected by the endogenous gene expression in develop-
ment and/or the adult mouse [45–49]. We hypothesize
that the KI mice may have expressed below detection
levels either due to being single-copy, EGFP, or both.
Notice also that the Ple94 MiniPromoter showed strong
expression in the striatum, a region of weak expression
with the ubiquitous promoter, thus expanding the
characterization of the viral tropism in this screening
system (Additional file 1: Figure S1). We also examined
the effect of the WPRE on expression specificity, and
noticed a very strong increase in the number of positive
cells with the Ple251 (C8ORF46 RRs) MiniP. While
Ple251-icre expressed in limited cortical layers, the
hippocampus, and the zona incerta; the addition of the
WPRE generalized expression to a near ubiquitous pat-
tern. This result suggests that in this system, WPRE
greatly enhances low-level and undetectable transcript
levels. In addition, the current set includes four con-
structs that expressed in putative glial cells (Ple266
(S100B RRs), Ple267 (UGT8 RRs), Ple304 (OLIG1 RRs),
and Ple305 (OLIG1 RRs)). Ple304 and Ple305 exhibited
highly similar expression patterns, despite changes to
the latter designed to strengthen expression. Finally,
using our Ple303 MiniP, we demonstrate similar expres-
sion to the previous BAC construct [2], indicating suc-
cess with our de novo design strategy.
Of course, negative, or partially negative results were
also obtained. First, minor base-pair modifications were
made to our previous Ple232 (TNNT1 RRs) MiniP,
resulting in Ple301. In doing so, surprisingly, we lost the
zona incerta brain expression seen previously in Ple232
KI mice [22], yet retained muscle specificity (Additional
file 1: Figure S3). This serves as an example where mov-
ing the promoter to virus and/or minor base-pair modi-
fication altered the function of the promoter in one cell
type, but not another. Second, when we tested hs671
and hs1218 each linked to the Hsp68 mouse basal pro-
moter as they were in the VISTA Enhancer project [38],
we did not observe the expected regional specificity to
either the forebrain or midbrain respectively (Additional
file 1: Figure S4). Expression was noted in those regions,
but similar expression was also detected throughout
most other brain regions. Thus, we deemed these two
constructs as being non-specific in our system. We
hypothesize that these VISTA enhancers may only re-
strict expression embryonically, and not postnatally. We
also tested from the literature PRS2/3:Con, a DBH-based
promoter that was successfully used in adenovirus in the
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rat brain [39]. However, we found that with intravenous
P0 delivery using rAAV it showed no expression differ-
ent from background. We hypothesize that this differ-
ence may have been due to the developmental stage of
delivery (P0 versus adult), the virus utilized, or the use
of human sequence in mouse versus rat.
In the second screening step, representative successful
promoters from step one were recloned driving the dir-
ect reporter EmGFP. Figure 4 demonstrates that the
Ple67 (FEV RRs) and Ple155 (PCP2 RRs) MiniPs drive
highly specific and expected expression when injected at
P4 in the temporal vein. Additional file 1: Figure S5 pre-
sents additional supportive data for both these MiniPs
injected at P0. Ple67 was derived from FEV, a gene
expressed in the serotonergic neurons of the raphe nu-
clei in the brain [50]. Previously, Ple67-EGFP and -lacZ
KI mice gave the expected raphe expression [22, 24].
Here, using rAAV, Ple67 again localized expression to
the raphe, which was further enhanced with the WPRE
(Fig. 4 and Additional file 1: Figure S5). Ple155 was
Fig. 3 Eight MiniPromoters in rAAVs show unique expression related to their source gene when driving icre in mice carrying a “lox-stop-lox-
lacZ” allele, an historical-indirect reporter. Each tEMS number indicates an individual animal. Ple94-icre (GPR88 RRs) expressed strongly in the
striatum and in upper cortical layers. Ple198-icre (SLC6A4 RRs) expressed in the thalamus and shows a clear demarcation between LGd and
LGv. Ple251-icre (C8ORF46 RRs) demonstrated strong expression in the hippocampus and cortex; layers IV, V, and Vb are predominant. The zona
incerta is also labeled. Ple251-icre-WPRE (C8ORF48 RRs) extended the expression to most brain regions, particularly throughout the cortex and in the
cerebellar granular layer. Ple266-icre (S100B RRs) expressed sporadically in the brain with puffy processes in the cortex and corpus callosum.
As expected for partial viral transduction, a subset of GFAP+ astrocytes are co-labelled with β-gal. Ple267-icre (UGT8 RRs) has strong staining in the
olfactory bulb and in the cerebellar granule layer, with some Purkinje cells labeled. In the OB, globeruli-like structures are stained. Ple303-icre (NOV RRs)
stains all cortical layers in midline and becomes specific to cortical layer V in more lateral sections. Ple304-icre and Ple305-icre (both
OLIG1 RRs) demonstrated an indistinguishable expression pattern with scattered cells in several brain regions, including the cortex and
brainstem, resembling puffy processes of oligodendrocytes. Bs, brainstem; Cb, cerebellum; Ctx, cortex; Hipp, hippocampus; icre, improved
cre recombinase; LGd, dorsal lateral geniculate; LGv, ventral lateral geniculate; Mb, midbrain; OB, olfactory bulb; RRs, regulatory regions;
Str, striatum; Th, thalamus. Blue, β-gal positive; brown, DAB immunohistochemistry; red, neutral red. [Scale bars = 100 μm]
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derived from PCP2, a gene expressed in the Purkinje
cells of the cerebellum [51, 52]. However, Ple155-lacZ
KI mice did not show this expected expression [22].
Thus, it was surprising when using rAAV, Ple155 gave
strong and consistent expression in the Purkinje cells
and their processes, which was further enhanced with
the WPRE (Fig. 4, Additional file 1: Figure S5). Since
expression with the ubiquitous promoters, even when
enhanced with WPRE, was limited in Purkinje cells
(Additional file 1: Figure S1), this result further expands
the characterization of the viral tropism in this system.
This result also suggests that KI at the Hprt genomic lo-
cation is not permissive for PCP2-based expression in
Purkinje cells, or that the presumed multi-copy expres-
sion of virus in Purkinje cells may push the reporter
above detection levels compared to the KI mouse. As
anticipated, negative MiniP results were also obtained.
Additional file 1: Figure S5 shows Ple264, which lacks el-
ements 12 and 13 compared to the original Ple140
(NR2E1 RRs). While Ple140 was strongly positive in the
hypothalamus of adult and embryonic KI mice [22, 24],
Ple264 lost the hypothalamic expression when delivered
in rAAV. This was presumably attributable to either the
“cut down” or the viral delivery system.
Figure 5 presents two examples where the MiniP has
been taken beyond screening, to modeling delivery ap-
plicable to gene therapy. For this, we evaluated the abil-
ity of Ple34 and Ple261 (CLDN5 RRs) to drive
expression in the endothelial cells of the blood brain
barrier, an important therapeutic target. Ple34 was previ-
ously positive driving lacZ in a KI mouse [24], and the
“cut down” version, Ple261 (Fig. 2), was tested driving
icre by temporal vein injection at P0. However, tail vein
injection in adult mice models a possible therapeutic
delivery, and allows evaluation of the expression with
a mature blood-brain barrier. Figure 5a and b res-
pectively, show consistent overlap of Ple34-miniSOG
(a fluorescent reporter chosen for its small size [53])
and Ple261-EGFP, with the endothelial cell marker
CD31. Importantly, MiniP-driven miniSOG or EGFP
co-labeling with endothelial markers in the liver
(CD16/CD32) and heart (CD31) was absent.
Overall, this data demonstrates that many of the Plei-
ades MiniPs expressed in rAAV according to their design
source and thus may be useful for rAAV-mediated
“gene-of-interest” delivery in the brain.
MiniPromoters for the eye include restricted expression in
bipolar ON cells and Müller glia
Due to developmental similarities, we anticipated that
many of the MiniPs designed for use in the brain would
also be applicable to basic, preclinical, and even clinical
use in ocular gene therapy. Thus, all 19 Pleiades MiniPs
tested in rAAV2/9 were examined for expression in the
eye after intravenous injection into neonatal mice. As in
the brain, the historical-indirect icre reporter system
gave a generalized pattern of positive staining that was
sparse but widespread. However, in some cases superim-
posed on this was the expected restricted expression. As
with the brain, only the GFP data is presented for
MiniPs selected for second-step screening to avoid du-
plication. In all, we obtained restricted expression in 10
MiniPs in the eye.
Fig. 4 Two MiniPromoters selected based on icre expression, recapitulated their unique expression related to their source gene when tested
driving EmGFP. Ple67-EmGFP ±WPRE (FEV RRs) drove expression in the dorsal raphe nuclei of the mouse brain. Ple155-EmGFP ±WPRE (PCP2 RRs)
drove expression in the Purkinje cells of the cerebellum, similar to the endogenous gene. In both cases, the presence of WPRE enhanced the number
of cells and intensity of cells showing expression. Cb, cerebellum; EmGFP, emerald green fluorescent protein; Raphe, raphe nuclei; RRs, regulatory
regions; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element. Blue, Hoechst 33342; Green, EmGFP immunofluorescence.
[Scale bars = 200 μm]
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Figure 6a presents the data for three positive Pleiades
MiniPs driving the historical-indirect reporter icre in the
retina of “lox-stop-lox-lacZ” mice after injection at P0.
Ple266 (S100B RRs) stained rare Müller glia (one of two
mice) above the background. Ple302 (DCX RRs) in-
tensely stained the retinal ganglion cell layer (GCL).
Ple302 is a “cut down” of Ple53 (Fig. 2), which in a KI
mouse showed expression in the GCL, but also
neurogenic regions of the brain [22, 24]. However, when
Ple302 was used in rAAV, the restricted brain expression
was lost, either due to the “cut down” or the viral deliv-
ery system. Notable is that the GCL is not a region of
endogenous DCX expression, but has been previously
observed with another promoter similar to Ple53 [54].
Finally, Ple303 (NOV RRs) showed some modest enrich-
ment in horizontal cells.
Fig. 5 Two CLDN5 RRs-based MiniPromoters (MiniPs) showed brain endothelial cell-specific expression related to their source gene, when virus
was introduced into the adult circulatory system. a The Ple34 MiniP drove expression of the miniSOG fluorescent green reporter in blood vessels
in the brain. Co-labelling was observed with CD31, a marker of endothelial cells. No miniSOG expression was detected in the heart where CD31
stains endocardial endothelium, or liver, where CD16/32 stains endothelial cells. b Ple261, a “cut down” of Ple34, also drove expression of EGFP in
blood vessels in the brain. Again, co-labelling was observed with CD31, a marker of endothelial cells, but no expression was detected in the heart
or liver. bp, base pairs; Ctx, cortex; EGFP, enhanced green fluorescent protein; miniSOG, mini Singlet Oxygen Generator; OB, olfactory bulb; RRs,
regulatory regions. [Scale bars = 50 μm]
de Leeuw et al. Molecular Brain  (2016) 9:52 Page 8 of 13
In the second screening step, MiniPs driving the direct
reporter EmGFP were positive in the retina and cornea
after injection at P4. In Fig. 6b retinal expression is pre-
sented. Ple67 (FEV RRs), showed expression primarily in
the GCL and inner nuclear layer, indicative of putative
ganglion and amacrine cells, which was enhanced by the
presence of the WPRE. Ple155 (PCP2 RRs) showed re-
stricted expression in bipolar ON cells. In this case, the
presence of the WPRE allowed enhanced visualization of
the cellular end feet. Note, comparison with previous work
demonstrates that the expression of Ple67 and Ple155 is
serotype and delivery-method independent [22, 55]. Finally,
Ple264 (NR2E1 RRs) gave strong Müller glia staining,
another gene therapy target [56]. Interestingly, Ple264
is a “cut down” of Ple140 which in KI mice expressed
strongly in the hypothalamus, but was completely
negative in the eye [22]. In Ple264, after the removal
of elements 12 and 13, the brain expression was lost,
either due to the “cut down” or viral delivery. How-
ever, Ple264 gained the NR2E1-endogenous expression
in Müller glia [57, 58], either due to removal of in-
hibitory sequences from the promoter, the multi-copy
rAAV system pushing the reporter above detection
levels compared to the KI mouse, or non-permissive
expression conditions at the Hprt genomic location
for NR2E1-based expression in the KI mouse.
In the cornea (Additional file 1: Figure S6), we ob-
served expression for five MiniPs driving icre (Ple251
(C8ORF46 RRs), Ple253 (PITX3 RR), hs671, Ple302
(DCX RRs), and Ple303 (NOV RRs), and one driving
EmGFP (Ple67 (FEV RRs)). Typically, expression was
stromal, but Ple251 also showed expression in the epi-
thelial layer of the cornea. In the case of Ple251-icre,
Ple253-icre, and Ple67-EmGFP, we were unable to detect
corneal expression without the use of the WPRE.
Overall, this data represents a rich resource of
therapeutically-enabling eye MiniPs that are likely to
have efficacy similar to the preclinical use of the Ple155
MiniP, which has already been used to restore vision in a
mouse model of congenital night blindness [55].
We have demonstrated that a single-step rAAV pipe-
line utilizing a direct reporter is sufficient for MiniP de-
velopment. We initially established a two-step screening
system, assuming we would need the sensitivity of a
historical-indirect reporter system to detect expression
from restricted promoters. However, we have found
there are disadvantages to such a sensitive system, and
that detection of the direct EmGFP reporter was not
Fig. 6 Six MiniPromoters (MiniPs) showed cell type-specific expression in the retina. a The icre reporter led to identification of three retina positive
MiniPs. Ple266-icre (S100B RRs) showed rare Müller glia expression as expected for the endogenous gene in one of two mice tested [69]. The
astrocytic layer also demonstrated some staining. Ple302-icre (DCX RRs) intensely stained the ganglion cell layer (GCL), similar to previous DCX-
based MiniPs [22]. For Ple303-icre (NOV RRs) we observed modest enrichment of staining in the outer side of the inner nuclear layer indicative of
horizontal cells. Blue, β-gal positive; red, neutral red. b Constructs utilizing the EmGFP reporter identified an additional three MiniPs with retinal
expression. In both cases tested, the presence of the WPRE enhanced the number and intensity of cells showing expression. Ple67-EmGFP ±WPRE
(FEV RRs) demonstrated expression primarily in the GCL and inner nuclear layer in putative ganglion and amacrine cells. Rarely, additional cells
were also positive with the WPRE-containing virus. Ple155-EmGFP ±WPRE (PCP2 RRs) restricted expression to bipolar ON cells. Ple264-EmGFP
(NR2E1 RRs) showed strong staining of Müller glial cells. EmGFP, emerald green fluorescent protein; GCL, retinal ganglion cell layer; icre, improved
cre recombinase; RRs, regulatory regions. [Scale bars = 100 μm]
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limiting, perhaps because of the multi-copy rAAV sys-
tem, although occasionally requiring anti-GFP immuno-
histochemistry or a WPRE for increased expression.
Importantly for this approach, we showed that the posi-
tive impact of WPRE was independent of MiniP, or open
reading frame, and that in the two cases for which cell
specificity could be best determined (Ple67-EmGFP and
Ple155-EmGFP (Figs. 4, 6)), expression in the brain and
retina was not “broadened” by WPRE. Given this data,
we suggest utilization of a single-step direct reporter and
the WPRE in future work.
The 16 MiniPs (human DNA elements designed to
drive expression in restricted cell types) presented here
are important advances for basic and preclinical re-
search, and may enable a paradigm shift in clinical gene
therapy. To assess the effectiveness of moving MiniPs
from KI mice to rAAV, we utilized five previous Pleiades
designs and 100 % showed expression related to the gene
and source. This demonstrates that the previously pub-
lished Pleiades MiniPs provide a rich resource of con-
structs for use in rAAV. However, many previous MiniPs
will still need to be “cut-down” for use in rAAV. Thus,
we undertook this work for eight Pleiades MiniPs, of
which five demonstrated expression related to their gene
and source, and two MiniPs maintained a further re-
stricted aspect of their previous expression. Therefore,
87.5 % maintained similar expression patterns despite
extensive size reduction. In addition, for one gene we
attempted, and successfully developed, a new promoter
rapidly and inexpensively. Finally, we demonstrate the
ability to test MiniPs directly in a single step in the
mouse EmGFP viral pipeline. Therefore, we provide ex-
tensive evidence for the utilization of a high-throughput
method of promoter design and testing in rAAV. These
MiniPs are now available unrestricted to the academic
community.
Methods
MiniPromoter bioinformatics and design
MiniPromoter (MiniP) bioinformatics has been described
in part, previously [24]. For our cut-downs and new designs
we considered the UCSC genome browser [59] tracks: EN-
CODE datasets [60–66], TFBS conserved, VISTA en-
hancers [38], UCSF brain methylation, ORegAnno [67, 68],
CpG islands, human mRNAs/ESTs, CD34 DNAse I, Repeat
Masker, and Conservation. For the Conservation tracks, we
utilized the mammalian conservation and Multiz align-
ments including placental mammals and vertebrates, but
excluded non-human primates to minimize selection bias
that may be introduced by high sequence similarities
between humans and primates. The following histone
modifications were considered: methylation of H3K4 and
H3K36 as indicators of transcriptional activation, methyla-
tion of H3K9 and H3K27 for transcriptional silencing, and
acetylation of H3K4 and H3K27 indicating transcriptional
activation. Tracks such as TFBS conserved, VISTA en-
hancers, and ORegAnno provide in silico and/or experi-
mental evidence for transcription factor binding sites and
regulatory regions. Tracks for DNAse I hypersensitivity,
such as CD34 DNAse I, help to mark regions that tend to
be associated with open chromatin structure and may con-
tain active binding sites. Potential regulatory regions were
rated as containing 1 to 5+ features; the highest scores typ-
ically being chosen for testing in MiniPs.
Mice
We purchased heterozygous 129S-Gt(ROSA)26Sortm1Sor/
J mice at N? + 9p (JAX Stock No: 003310) and continued
backcrossing the allele onto the 129S1/SvImJ strain
(JAX Stock No: 002448) until N13. Heterozygous mice
were then intercrossed to obtain a congenic homozygous
strain. We also purchased homozygous B6.129S4-Gt(RO-
SA)26Sortm1Sor/J mice at N4F10N1p (JAX Stock No:
003474) and restarted backcrossing the allele onto the
C57BL/6J strain (JAX Stock No: 000664) until N11. Het-
erozygous mice were then intercrossed to obtain a con-
genic homozygous strain. All experimental mice were
B6129F1 hybrids and generated either as the first gener-
ation of crossing a congenic homozygous 129S-Gt(RO-
SA)26Sortm1Sor/JEms to a congenic homozygous
B6.129S4-Gt(ROSA)26Sortm1Sor/JEms, or C57BL/6J to
129S1/SvImJ. For clarity, we describe mice carrying the
Gt(ROSA)25Sortm1Sor allele as containing a “lox-stop-lox-
lacZ” reporter, which we utilized as an indirect-historical
marker of cre-recombinase expression.
Virus generation and analysis
Virus production
We generated a “plug and play” rAAV2 genome plasmid
that included AAV2 inverted terminal repeats (ITR), and
allowed for the easy exchange of promoters, intron,
reporters, and 3’ UTR elements using restriction enzymes.
In this study we tested the 3’ UTR element WPRE (wood-
chuck hepatitis virus post-transcriptional regulatory elem-
ent) mut6 [32, 33]. MiniPs were isolated from existing
Pleiades Promoter plasmids [22, 24], or generated by
direct synthesis (DNA2.0, Menlo Park, CA, USA), and
cloned into the multiple-cloning site (MCS) of a new
“plug and play” rAAV2 genome plasmid - either the
pEMS1987 backbone containing the improved cre (icre)
reporter [28], and/or the pEMS2157 backbone containing
the emerald green fluorescent protein (EmGFP) reporter
[29]. Plasmids were propagated in the E. coli SURE Cells
(Agilent Technologies, Santa Clara, CA, USA). One to five
μg of plasmid DNA containing the MiniP was prepared by
QIAgen Spin MiniPrep Kit (Catalog #27104, QIAgen,
Germantown, MD, USA). rAAV plasmid DNAs was
demonstrated free of rearrangements by AhdI digest, ITRs
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verified via SmaI single digests, and overall structure via
AscI/EcoRI double digestion, and upon confirmation, sent
to the Vector Core at the University of Pennsylvania
(Philadelphia, PA, USA) for large-scale DNA amplification
using the EndoFree Plasmid Mega Kit (Catalog #21381,
QIAgen, Germantown, MD, USA). Quality control on the
plasmid preparation was done via SmaI, PvuII, and SnaBI
confirmatory digests, and subsequently packaged into
rAAV2/9 serotype virus. Ple34-miniSOG and Ple261-
EGFP were cloned, DNA amplified, and packaged into
AAV2/9 in the laboratory of A.A. for adult intravenous
experiments.
Virus injection
B6129F1 hybrid pups were either homozygous for the
Gt(ROSA)26Sortm1Sor allele for icre virus injections, or
wild type at that locus for EmGFP virus injections.
Timed pregnancies were achieved using crowded fe-
males, experienced studs, and plug checking of females
such that the day of birth could be accurately predicted.
Virus injections were into postnatal (P) 0 (the day of
birth) pups for icre constructs, and P4 for EmGFP con-
structs. For P0, if the female gave birth over night or in
the morning, virus was injected in the afternoon. If she
gave birth in the afternoon, virus was injected the next
morning. Standard P0 and P4 pup injections were into
the superficial temporal vein using 1 × 1013 GC/mL
(genome copies per milliliter) virus in a volume of 50 μL
(in PBS) with a 30-gauge needle and a 1 cc syringe. After
injection, pups were tattooed for identification and
returned to their cage. Ple34-miniSOG (dose of 3 × 1011
viral genomes) and Ple261-EGFP (dose of 8 × 1011 viral
genomes) virus were injected intravenously at 6–8 weeks
via tail vein.
Harvesting of animals
Virus-injected mice were harvested at P21 or P56. Ani-
mals were given a lethal dose of avertin injected intra-
peritoneally. Thereafter, perfusion with 1xPBS for 2 min
and 4 % PFA/PBS for 8 min was performed. Brain, eye,
spinal cord, and heart were harvested and post-fixed for
2 h at 4 °C. The tissues were then stored in 0.01 %
azide/PBS at 4 °C. Ple34-miniSOG and Ple261-EGFP
mice were harvested 4 weeks post injection.
Histology
Reporter gene expression was usually analyzed at P21 or
P56 in brain, eye, spinal cord, and heart. Tissues were
cryoprotected in 25 % sucrose/PBS overnight at 4 °C.
After embedment in OCT (optimal cutting temperature
compound) the following day, 20 μm sections were
directly mounted onto slides. For X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galacto-pyranoside) staining, tis-
sues were rinsed in PBS and Triton-X/PBS and stained
in 0.1 % X-gal solution overnight (~18 h) at 37 °C. After
staining, sections were rinsed and counterstained with
neutral red, dehydrated, and mounted with coverslips.
For co-labeling of X-gal with markers using immuno-
histochemistry, standard procedures were followed
and the X-gal stain was performed either prior to pri-
mary antibody incubation or between primary and
secondary antibodies, depending on the strength of
the X-gal stain. X-gal stains blue any cells that have
recombined the “lox-stop-lox-lacZ” reporter locus due
to icre recombinase activity and thus expressing the
β-galactosidase protein. With the icre reporter, we
detected historical and indirect expression of the
promoter.
EmGFP constructs were signal amplified using a
chicken α-GFP antibody (Aves Labs Inc.; 1:500) and
Alexa Fluor 488 secondary (Life Technologies; 1:1000).
With the EmGFP fluorescent reporter, we visualized dir-
ect expression. Ple34-miniSOG and Ple261-EGFP mice
were analyzed for green epifluorescence (miniSOG or
EGFP) and co-stained with markers of endothelial cells
(brain and heart: CD31; liver: CD16/CD32).
Imaging
Between four and twelve animals were studied for each
MiniPromoter, and unique expression patterns of the
MiniPs were determined by microscope and image ana-
lyses. The images shown are typically from mice that
had the most successful injections and thus the full dose
of rAAV, and therefore the greatest likelihood to observe
off-target expression if present. Brightfield and fluores-
cence images were standardly taken using an Olympus
BX61 motorized microscope or a Zeiss 710 Confocal
Laser Scanning Microscope. Images were processed
using ImageJ (http://rsbweb.nih.gov/ij/), Photoshop, and
Illustrator (Adobe, San Jose, CA). Brightness, contrast,
and color balancing adjustments, as per Molecular Brain
guidelines, were made where necessary to improve
visibility.
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Materials and data availability
All MiniPs and constructs have been deposited with
AddGene (www.addgene.org), with the exception of those
constructs used in generating Fig. 5 – these are available
from A.A. upon request (aravind_asokan@med.unc.edu).
Additional file
Additional file 1: Supplementary Figures 1 - 6. (PDF 10 kb)
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